Asad Haider
Stock Analyst at Goldman Sachs
(4.59)
# 808
Out of 4,587 analysts
121
Total ratings
84.3%
Success rate
23.9%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintained: Buy | $282 | $258.24 | +9.20% | 22 | Jul 27, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,283 | $1,144.53 | +12.10% | 23 | Jul 24, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $137 | $130.38 | +5.08% | 19 | Jul 23, 2026 | |
| ABBV AbbVie | Maintained: Hold | $244 | $251.52 | -2.99% | 8 | Jul 21, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $61 | $65.13 | -6.34% | 11 | Jul 20, 2026 | |
| PFE Pfizer | Maintained: Hold | $26 | $25.15 | +3.38% | 19 | Jun 23, 2026 | |
| RPRX Royalty Pharma | Rated: Buy | $51 → $59 | $58.61 | +0.67% | 3 | May 7, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Hold | $37 → $38 | $27.84 | +36.49% | 4 | May 7, 2026 | |
| INVA Innoviva | Maintained: Sell | $17 → $18 | $20.99 | -14.24% | 2 | May 6, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $132 → $133 | $91.08 | +46.03% | 5 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $38 → $67 | $54.50 | +22.94% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $386.14 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $13.49 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $168 | $165.71 | n/a | 1 | Dec 14, 2018 |
Johnson & Johnson
Jul 27, 2026
Maintained: Buy
Price Target: $282
Current: $258.24
Upside: +9.20%
Eli Lilly and Company
Jul 24, 2026
Maintained: Buy
Price Target: $1,283
Current: $1,144.53
Upside: +12.10%
Merck & Co.
Jul 23, 2026
Maintained: Buy
Price Target: $137
Current: $130.38
Upside: +5.08%
AbbVie
Jul 21, 2026
Maintained: Hold
Price Target: $244
Current: $251.52
Upside: -2.99%
Bristol-Myers Squibb Company
Jul 20, 2026
Maintained: Hold
Price Target: $61
Current: $65.13
Upside: -6.34%
Pfizer
Jun 23, 2026
Maintained: Hold
Price Target: $26
Current: $25.15
Upside: +3.38%
Royalty Pharma
May 7, 2026
Rated: Buy
Price Target: $51 → $59
Current: $58.61
Upside: +0.67%
NewAmsterdam Pharma Company
May 7, 2026
Maintained: Hold
Price Target: $37 → $38
Current: $27.84
Upside: +36.49%
Innoviva
May 6, 2026
Maintained: Sell
Price Target: $17 → $18
Current: $20.99
Upside: -14.24%
BioNTech SE
May 5, 2026
Maintained: Buy
Price Target: $132 → $133
Current: $91.08
Upside: +46.03%
Feb 26, 2026
Maintained: Hold
Price Target: $38 → $67
Current: $54.50
Upside: +22.94%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $386.14
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $13.49
Upside: n/a
Dec 14, 2018
Maintained: Buy
Price Target: $168
Current: $165.71
Upside: n/a